Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by TheRock07on Nov 11, 2016 10:05am
126 Views
Post# 25449102

RE:RE:RE:RE:Q3 Report...Very Good but US not so

RE:RE:RE:RE:Q3 Report...Very Good but US not soCPH traded in the $15 range in 2015, on its very strong cash flowing canadian assets.

Subequent to the April 2015 acqusition of its US assets, it share price has progressively traded downwards.

It was stated at the time that the US asset would become accretive in 2017.

That may yet happen, but they have a lot of work to do yet.

Should they sell the US assets, CPH would once again rise above $10.

This is my ideal outcome, as they wont get as much for a sale as they would from the market.

Insiders own a whack of shares, so perhaps they may concentrate on selling the US assets while continueing to advance their strong Canadian assets which have several more drugs entering the revenue streams in 2017
Bullboard Posts